Electrodes in the brain—Ethical criteria for research and treatment with deep brain stimulation for neuropsychiatric disorders
Section snippets
Setting the stage
High-frequency electrical deep brain stimulation (DBS) of specific brain circuits has gained increasing acceptance in treatment of several neurologic disorders because of its high effectiveness and—compared with classical ablative neurosurgical interventions—its less invasive, largely reversible, and adjustable features.1 First evidence for efficacy has also been shown in studies of treatment-refractory psychiatric diseases, such as obsessive-compulsive disorder2, 3, 4, 5 and major depression6,
Ethical criteria for neuropsychiatric DBS—Stepping beyond common ethical references
Many current ethical perspectives draw on references to early psychosurgery17, 20 or the risk to alter a patient's personality15, 21 to delineate negative ethical criteria for psychiatric DBS. However, these references are of rather limited value for establishing positive ethical criteria that can be systematically applied in current research and clinical DBS to perform evidence-based ethical decision-making processes.22
At first sight, there is no need for specific ethical criteria for DBS in
Implementing procedural safeguards
Obviously, the specific challenges in assessing benefit, harm, and autonomy do not present a general argument to not perform DBS in psychiatric patients, yet they put emphasis on the need to carefully scrutinize DBS considerations, to study effects and adverse events with different outcome measures and methodologies and to openly report any kind of short- or long-term adverse events. In addition, like in other vulnerable populations (e.g., DBS in children with movement disorders or in Parkinson
Level of evidence for DBS efficacy and safety
So far, most available data about psychiatric DBS has been uncontrolled, thus raising the question what level of evidence should be used to establish safety and efficacy. This complex question cannot be addressed here in full detail, but from an ethical perspective it seems obvious to ask for randomized controlled trials as only they can establish true efficacy and rule out possible confounding factors, previously described. It was well shown for DBS in Parkinson's disease,34 primary dystonia,35
Conclusion
DBS might turn out to be a focused and efficacious treatment option for well-selected psychiatric patients resistant to traditional methods, and maybe also in the future for those patients who show a significant, yet still insufficient effect to other treatments. There are no inherent ethical objections; the same ethical criteria that are already widely used to assess other biomedical interventions can be productively applied for analyzing DBS studies and for clinical decision making. These
References (71)
- et al.
Deep brain stimulation for refractory obsessive-compulsive disorder
Biol Psychiatry
(2005) - et al.
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Biol Psychiatry
(2008) - et al.
Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression
Biol Psychiatry
(2009) - et al.
Deep brain stimulation in psychiatry: concentrating on the road ahead
Biol Psychiatry
(2009) - et al.
Deep brain stimulation for treatment-resistant depression
Neuron
(2005) - et al.
Deep brain stimulation for treatment of refractory depression
Lancet
(2005) The primate basal ganglia: parallel and integrative networks
J Chem Neuroanat
(2003)- et al.
Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in extremely treatment-resistant depression
Biol Psychiatry
(2010) - et al.
Manic episode with psychotic symptoms in a patient with Parkinson's disease treated by subthalamic nucleus stimulation: improvement on switching the target
J Neurol Sci
(2008) Diagnosis and definition of treatment-resistant depression
Biol Psychiatry
(2003)
Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome
Neuropsychopharmacology
Deep brain stimulation
Annu Rev Neurosci
Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder
Neuropsychopharmacology
Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder
Neurosurgery
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder
N Engl J Med
Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression
Neuropsychopharmacology
Neurosurgical implants: clinical protocol considerations
Camb Q Healthc Ethics
A leg to stand on: Sir William Osler and Wilder Penfield's “neuroethics”
Am J Bioeth
Ethics in the clinical application of neural implants
Camb Q Healthc Ethics
Stimulating brains, altering minds
J Med Ethics
Ethical issues surrounding deep brain stimulation in Parkinson's disease
JAAPA
Deep brain stimulation: avoiding the errors of psychosurgery
Jama
Deep brain stimulation and the ethics of protection and caring for the patient with Parkinson's dementia
Mov Disord
Deep brain stimulation, neuroethics, and the minimally conscious state: moving beyond proof of principle
Arch Neurol
Neuropsychiatry: rewiring faulty circuits in the brain
Science
Electrodes in the brain: some anthropological and ethical aspects of deep brain stimulation
Int Rev Information Ethics
Stimulating personality: ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes
Biotechnol J
Principles of biomedical ethics
Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder
Neuropsychopharmacology
Parkinson's disease: neurosurgery at an earlier stage?
J Neurol Neurosurg Psychiatry
Clinical predictive factors of subthalamic stimulation in Parkinson's disease
Brain
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial
Neurology
Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration
Brain
Cited by (0)
Dr. Schlaepfer received limited support for an Investigator Initiated Study on DBS in resistant major depression from Medtronic Inc., a manufacturer of DBS equipment between 2004 and 2007.